发明名称 |
PHARMACEUTICAL COMPOSITION CONTAINING LIRIODENDRON TULIPIFERA L. EXTRACT FOR TREATING CHRONIC MYELOGENOUS LEUKEMIA |
摘要 |
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a Liriodendron tulipifera L. bark extract for treating chronic myelogneous leukemia. More specifically, the present invention relates to the pharmaceutical composition, containing, as the active ingredient, the Liriodendron tulipifera L. bark extract useful in selectively inhibiting mutant enzyme T315I from a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, and to a use of epi-Tulipinolide which is an active ingredient of the composition. |
申请公布号 |
US2016081978(A1) |
申请公布日期 |
2016.03.24 |
申请号 |
US201414786329 |
申请日期 |
2014.04.23 |
申请人 |
CHO DANG PHARM. CO., LTD. |
发明人 |
KIM Ki Woon;YOO Hye Dong;HONG Soon Sun;KIM Soo Jung;LEE Hyun Seung;FANG Zhenghuan;KANG Su Jin |
分类号 |
A61K31/365;A61K36/57 |
主分类号 |
A61K31/365 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical composition containing epi-tulipinolide as active ingredient from the extract of the bark of Liriodendron tulipifera for treating chronic myeloid leukemia (CML) by selectively inhibiting T315I enzyme variant expressed from BCR-ABL fusion gene. |
地址 |
Seoul KR |